Taimed Biologics Stock Revenue
| 4147 Stock | TWD 79.90 1.30 1.65% |
TaiMed Biologics fundamentals help investors to digest information that contributes to TaiMed Biologics' financial success or failures. It also enables traders to predict the movement of TaiMed Stock. The fundamental analysis module provides a way to measure TaiMed Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TaiMed Biologics stock.
TaiMed |
TaiMed Biologics Company Revenue Analysis
TaiMed Biologics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current TaiMed Biologics Revenue | 413.44 M |
Most of TaiMed Biologics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TaiMed Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, TaiMed Biologics reported 413.44 M of revenue. This is 94.58% lower than that of the Biotechnology sector and 44.35% lower than that of the Health Care industry. The revenue for all Taiwan stocks is 95.62% higher than that of the company.
TaiMed Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TaiMed Biologics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TaiMed Biologics could also be used in its relative valuation, which is a method of valuing TaiMed Biologics by comparing valuation metrics of similar companies.TaiMed Biologics is currently under evaluation in revenue category among its peers.
TaiMed Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.062 | |||
| Profit Margin | (1.70) % | |||
| Operating Margin | (1.47) % | |||
| Current Valuation | 17.73 B | |||
| Shares Outstanding | 252.37 M | |||
| Shares Owned By Insiders | 17.27 % | |||
| Shares Owned By Institutions | 21.66 % | |||
| Price To Book | 6.45 X | |||
| Price To Sales | 55.99 X | |||
| Revenue | 413.44 M | |||
| Gross Profit | 177.82 M | |||
| EBITDA | (306.83 M) | |||
| Net Income | (470.93 M) | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 4.03 X | |||
| Total Debt | 536 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 10.64 X | |||
| Book Value Per Share | 10.88 X | |||
| Cash Flow From Operations | (211.28 M) | |||
| Earnings Per Share | (2.36) X | |||
| Target Price | 88.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.51 | |||
| Market Capitalization | 17.62 B | |||
| Total Asset | 4.61 B | |||
| Z Score | 19.2 | |||
| Net Asset | 4.61 B |
About TaiMed Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TaiMed Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TaiMed Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TaiMed Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with TaiMed Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TaiMed Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TaiMed Biologics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to TaiMed Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TaiMed Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TaiMed Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TaiMed Biologics to buy it.
The correlation of TaiMed Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TaiMed Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TaiMed Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TaiMed Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.